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CytogeneticsSummary Cytogenetic abnormalities of chromosome 12p involving the TEL/ETV6 gene are observed in
a variety of hematopoietic neoplasms including acute leukemias, myelodysplastic syndromes, and
myeloproliferative disorders. Karyotypic aberrations, including rearrangements, deletions, and
amplifications of chromosome 12p, have been documented in B-cell non-Hodgkin lymphoma;
however, rearrangements targeting TEL have rarely been reported. Here we describe a diffuse large B-
cell lymphoma that had a complex karyotype including t(9;12)(q22;p13), which was confirmed by
fluorescence in situ hybridization to represent rearrangement of TEL. Additional cytogenetic
abnormalities included t(3;14)(q27;q32) involving the variant, alternative breakpoint region of the
BCL6 gene and del(6)(q13q23), resulting in the loss of 1 allele of BLIMP1. This case reiterates the
importance of correlating morphologic and phenotypic findings with the results of cytogenetic analysis
to avoid errors in diagnosing hematologic neoplasms and highlights the rare association of B-cell non-
Hodgkin lymphoma with aberrations of TEL.
© 2009 Elsevier Inc. All rights reserved.1. Introduction presented with multiple lytic bone lesions and pleuralTranslocations and deletions of chromosome 12p13
involving the TEL gene occur in a variety of hematologic
neoplasms, including acute myeloid and lymphoblastic
leukemias, myelodysplastic syndromes (MDSs), and mye-
loproliferative disorders [1,2]. Aberrations of 12p have also
been reported in 15% to 22% of B-cell non-Hodgkin
lymphomas (B-NHLs); however, the targeted genes are not
yet known in most cases [3,4]. We report a unique case of
diffuse large B-cell lymphoma (DLBCL), which occurred in
a child with history of classic Hodgkin lymphoma and⁎ Corresponding author. Department of Pathology, College of Physi-
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oi:10.1016/j.humpath.2008.08.012effusions at relapse. The lymphoma had a complex
karyotype, which included translocation of 12p13 that was
confirmed to involve the TEL gene; rearrangement involving
the variant, alternative breakpoint region (ABR) of the BCL6
gene; and 6q deletion.2. Methods
The computed tomography–guided biopsy of a lytic
lesion of the lumbar vertebral body (L5) and a cell block
prepared from the pleural fluid were fixed in formalin (10%
neutral buffered). Paraffin-embedded sections of these
specimens were stained with hematoxylin and eosin, and a
cytospin preparation was stained with Wright-Giemsa for
morphologic review.
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and flow cytometry
Immunohistochemical (IHC) stains were performed on
the vertebral bone biopsy and pleural fluid cell block with
the primary antibodies CD20, PAX5, BCL6, CD10, MUM1,
BCL2, CD5, CD3, Ki-67, and p53 after heat-induced
antigen retrieval; and Envision plus (DAKO, Carpinteria,
CA) and diaminobenzidine (DAB) were used for visualiza-
tion. IHC staining for TEL was also performed on the bone
biopsy using an antibody directed against ETV6 (clone
HPA000264, rabbit polyclonal; Sigma, St Louis, MO). In
situ hybridization for Epstein-Barr virus–encoded small
RNAs (EBER) was performed using the supplied protocol
(INFORM EBER; Ventana, Tucson, AZ).
Four-color flow cytometry of the pleural fluid was
performed using FACSCalibur (Becton Dickinson, San
Diego, CA) and the following primary antibodies: CD45,
CD19, CD20, CD10, CD43, κ and λ light chains, CD3,
CD16, and CD56 (Becton Dickinson). Data were analyzed
using Cellquest software (Becton Dickinson).
2.2. Cytogenetic analysis
Giemsa banding was performed on metaphase prepara-
tions obtained after short-term (12 hours) culture of the
pleural fluid using standard methods. Fluorescence in situ
hybridization (FISH) analyses were performed on methanol-
acetic–fixed cells using IGH, BCL6(3q27), TEL/ETV6
(12p13), and c-MYC(8q24) dual-color break-apart probes
(VYSIS, Downers Grove, IL); a locus specific probe for
BLIMP1(PRDM1)(6q21) [5]; and a CEP6 probe (VYSIS),
according to standard protocols; and 200 to 300 cells were
analyzed. Fluorescence signals were captured after counter-
staining with 4′-6-diamidino-2-phenylindole (DAPI) using
the Cytovision Imaging system attached to a Nikon Eclipse
600 microscope (Applied Imaging, Santa Clara, CA).
2.3. Immunoglobulin heavy chain gene rearrangement
Polymerase chain reaction analysis to detect rearrange-
ment of the immunoglobulin heavy chain gene variable
region was performed on a pleural fluid specimen using the
Biomed-2 primers (IVS Gene Clonality Assay Kit; InVivo-
Scribe Technologies, San Diego, CA).
2.4. Case report
A 22-year–old woman was diagnosed with stage 4B
classic Hodgkin lymphoma, nodular sclerosis type, 8 yearsFig. 1 A, Cytospin of pleural fluid showing large pleomorphic
lymphocytes (Wright-Giemsa, 400×). B, Vertebral body biopsy
showing an infiltrate of DLBCL (hematoxylin and eosin, 400×),
with (C) intense nuclear staining for TEL (ETV6, 400×).
590 D. W. Sevilla et al.before her current presentation. She was refractory to a
variety of chemotherapeutic regimens, including 8 cycles of
COPP-ABVD (cyclophosphamide, prednisone, procarba-
zine, vincristine, bleomycin, dacarbazine, doxorubicin,Fig. 2 A, G-band karyotype obtained from culture of pleural fluid. Arro
break-apart probes shows 1 green (split) signal on the short arm of the abn
abnormal chromosome 9 consistent with TEL translocation (arrows). A sin
C, FISH with BCL6 break-apart probe shows 1 small red signal (arrow)
signal (unequal split, arrowhead) on the long arm of chromosome 3 consis
on the nonrearranged chromosome 3 is also present.vinblastine) followed by 2 cycles of ICE (carboplatin,
etoposide, ifosfamide), high-dose BCNU(carmustine), etopo-
side, and autologous stem cell rescue, experiencing multiple
relapses. Remission was eventually achieved after 10 cyclesws indicate t(9;12), t(3;14), and del(6q)(q13q23). B, FISH with TEL
ormal chromosome 12 and 1 red (split) signal on the long arm of the
gle yellow (fusion) signal is present on the normal chromosome 12.
translocated to the long arm of chromosome 14 and 1 green-yellow
tent with ABR translocation; 1 yellow (fusion) signal (normal allele)
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and axilla) radiation. Three years before presentation at our
institute, she developed pancytopenia; and a bone marrow
biopsy showed an infiltrate of DLBCL. She was then treated
with CHOP (cyclophosphamide, doxorubicin, prednisone,
vincristine) in conjunction with vincristine, cyclophospha-
mide, prednisone, doxorubicin, and rituximab for 6 months,
again relapsing with bone marrow and central nervous system
involvement. She was started on the COG 5961 (group C)
consolidation-phase regimen with high-dose Ara-C and
etoposide with rituximab, intrathecal triple therapy, and
conditioning with fludarabine and busulfan in preparation for
a bone marrow transplant. She then underwent a reduced-
intensity stem cell transplant from her mother 4 months
before current presentation. Her most recent presentation was
due to development of a large left pleural effusion, and
positron emission tomographic scans showed increased
uptake in the sternal manubrium and the L5 vertebral body.
Cytologic examination of the pleural fluid was notable
for increased numbers of large atypical lymphocytes that
had large round to ovoid nuclei, with occasional cells
showing irregular nuclear contours, fine chromatin, multiple
small nucleoli, and moderate to abundant basophilic
cytoplasm (Fig. 1A). Biopsy of the vertebral lytic bone
lesion revealed an infiltrate of large lymphocytes with
similar morphologic features (Fig. 1B). Flow cytometry of
the pleural fluid showed a population of λ-light chain
restricted medium to large B-cells exhibiting intermediate to
high forward scatter; bright CD45, CD19, CD20, and CD43
expression; and dim, partial CD10 expression. IHC staining
of the vertebral bone biopsies and pleural fluid cell block
demonstrated the following phenotypes of the neoplastic
cells: CD20+, PAX5+, BCL6+, MUM1+, BCL2+, and
CD43+. The lymphocytes also showed intense nuclear
staining for TEL protein (Fig. 1C). The proliferation index,
as assessed with a Ki-67 stain, was markedly elevated
(90%). Aberrant nuclear expression of p53 was seen in most
cells (80%). Result of in situ hybridization for Epstein-Barr
virus (EBER) was negative.
Cytogenetic analysis performed on the pleural fluid
sample showed a complex karyotype (Table 1, Fig. 2A).
FISH using the ETV6 (TEL)(12p13) break-apart probe
confirmed rearrangement of TEL (split red and green signals,
Fig. 2B). A probe for BLIMP1(PRDM1)(6q21) indicated
loss of 1 copy of BLIMP1. IGH and BCL6 break-apart
probes confirmed t(3;14). However, the signal pattern
(unequal split of signals) was consistent with a break 5′ to
the BCL6 gene, involving the ABR (Fig. 2C). No MYC
translocation was detected by FISH analysis.
A clonal product was detected by polymerase chain
reaction for immunoglobulin heavy chain rearrangement in
the pleural fluid sample. Together, these findings were
diagnostic of a DLBCL involving the lumbar spine and
pleural fluid.
The patient was admitted for management of her pleural
effusion and consideration of another bone marrow trans-plant. Her hospital course was complicated by sepsis, renal
failure, and disseminated intravascular coagulation; and she
died shortly after admission.3. Discussion
We describe a case of DLBCL with a complex karyotype
and rearrangement of the TEL gene. To the best of our
knowledge, this is only the fourth reported case of B-NHL
with TEL rearrangement (Table 1) [6-8]. The precise
morphologic, phenotypic, and clinical details of 2 cases are
unknown because they were reported only as B-NHL that
occurred in a 4-year–old girl [7] and a 30-year–old man [6].
The third reported case [8] was of a marginal zone lymphoma
occurring in a 70-year–old man with involvement of the
bone marrow, blood, lymph node, and spleen. That patient
was alive 10 months after treatment with chlorambucil.
Rearrangements involving the TEL gene (also known as
the E26 transforming specific [ETS] translocation variant
gene 6; ETV6) are frequently detected in a variety of
hematopoietic neoplasms, specifically acute leukemias,
MDSs, and myeloproliferative disorders [1,2]. However,
since the initial characterization of this gene and identifica-
tion of TEL rearrangements and deletions over a decade ago,
the function of TEL remains unclear. Structural studies have
demonstrated that TEL contains both a 3′ ETS DNA binding
domain, which also mediates protein-protein interactions,
and a 5′ helix-loop-helix domain involved in homo-and
heterodimerization of transcription factors and signal
transducing proteins [9]. TEL is involved in chromosomal
translocations with a variety of partners forming chimeric
fusion transcripts (eg, TEL-PDGFRB, TEL-ABL, TEL-
AML1), and the function of TEL is thought to differ
depending on the fusion partner. Bohlander [1] subdivided
the fusion partners into different functional groups, for
example, tyrosine kinases, transcription factors, as well as
“unproductive fusions,” in an attempt to further elucidate the
role of TEL in hematologic disorders. Within the first
category, TEL partnering with JAK2, a tyrosine kinase
fusion protein, leads to constitutive activation of the protein
tyrosine kinase domain [10], whereas in cases of TEL-AML1
rearrangement, it is hypothesized that the chimeric fusion
protein causes constitutive repression of AML1 leading to
deregulation of AML1 target genes [11]. Finally, in addition
to rearrangements involving TEL and formation of fusion
genes or protooncogene activation, recurrent loss of genetic
material from 12p13, the region containing the TEL gene, is
also frequently described, suggesting possible function as a
tumor suppressor. In many hematologic disorders with TEL
rearrangement, deletion of the nonrearranged allele of TEL
occurs in 60% to 75% of cases [3,7]. Such a concomitant
deletion was described in 2 of the previous B-NHLs with
TEL rearrangement (cases 3 and 4), but was not detected in
our case (Table 1). Of note, allelic loss of a microsatellite
Table 1 B-NHLs with TEL rearrangements
Case Age/Sex G-band karyotype Diagnosis Ref
1 22/F 46, XX,t(3;14)(q27;q32),del(6)(q13q23),t(9;12)(q22;p13),
del(20)(q11.2)[11]/46,idem,t(1;16)(q44;p13.1)[9]
DLBCL Current case









Abbreviation: MZBCL, marginal zone B-cell lymphoma.
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of follicular lymphoma [4], further supporting a tumor-
suppressor function in certain contexts. It would be of
interest to see if other mechanisms leading to loss of function
of TEL (eg, mutations) play a role in progression of B-NHL.
Our case demonstrated TEL rearrangement with the locus
9q22, a region that has previously not been described in B-
NHL. However, rearrangement involving this locus has been
reported in a case of MDS [12]. In the latter, the fusion
partner on 9q22 was identified as tyrosine kinase gene Syk;
and the TEL-Syk fusion was shown to lead to interleukin-3–
independent growth of Ba3 cells [12].
The time of acquisition of TEL rearrangement in our case
is not clear because cytogenetic analysis was not performed at
the time of primary presentation of the DLBCL. It is possible
that the translocation of TEL occurred later during clonal
evolution. The patient had received multiple chemotherapeu-
tic regimens for both Hodgkin lymphoma and DLBCL; and
thus, a role, if any, of these agents in inducing rearrangement
of TEL cannot be excluded. A role of TEL in mediating
resistance to chemotherapy is also unclear. Of note, 3 of the 4
B-NHLs with TEL translocations (including our case) had a
complex karyotype (Table 1). Thus, as has been previously
hypothesized, TEL rearrangement in these cases may
represent a class II mutation, blocking differentiation and/or
interfering with apoptosis, and, although required, is not
sufficient for development of malignancy [13].
In the absence of fresh or frozen material, we could not
analyze the messenger RNA expression level of TEL.
However, intense nuclear staining for TEL was observed in
the neoplastic lymphocytes by IHC analysis. This finding is
suggestive of TEL overexpression because normal lymph
node and tonsillar B-cells did not show any staining for TEL.
It is unclear at present whether mechanisms other than
translocations can also lead to deregulated expression of TEL
in certain B-NHLs because a survey of TEL messenger RNA
or protein expression in B-NHLs has not been performed. It
should be mentioned that although we observed over-
expression of TEL, the functional status of TEL protein in
our case is unknown.
Other genes on chromosome 12p have been previously
implicated in B-NHL. These include p27Kip1, a cyclin-dependent kinase inhibitor located centromeric to TEL,
which is expressed in lower levels in high-grade B-NHL,
including DLBCL and mantle cell lymphoma [14-16]. The
cyclin-D2 gene (CCND2) is located telomeric to TEL.
Cyclin D2 overexpression via amplification or rearrange-
ment with immunoglobulin heavy or light chains has been
described in mantle cell lymphoma and more rarely in other
B-NHLs, including Burkitt lymphoma and chronic lympho-
cytic leukemia (at transformation) [3,17-19]. Rearrange-
ments involving 12p are often accompanied by deletions in
the adjacent regions. Because the size of the deletions is
often large, at times encompassing the loci of both TEL and
p27Kip1, an impact of a loss of individual genes, or a
combination of both, on disease inception or evolution of
previously reported cases is unknown [3,6,7]. The findings
of G-band karyotype and FISH ruled out structural
aberrations of p27Kip1 and CCND2 in the current case.
In addition to rearrangement of TEL, our DLBCL
demonstrated a translocation involving the ABR of the
BCL6 gene. This breakpoint is located between 245 and 285
kilobases 5′ to BCL6, and translocations involving this
region are more commonly seen in follicular lymphomas;
however, they are also detected in approximately 12% of
DLBCLs with 3q27 translocation and 4% of DLBCLs
overall [20]. Karyotype analysis also showed deletion of 6q,
and FISH confirmed loss of 1 allele of the BLIMP1 gene.
BLIMP1 is a transcriptional repressor that is required for
terminal B-cell differentiation. Alterations or loss of
BLIMP1 has been described in 25% of activated B-cell
like DLBCLs and are considered uncommon in germinal
center B-cell like DLBCLs [5]. Because BCL6 translocations
and BLIMP1 deletions are considered mutually exclusive
events [5], it has been hypothesized that alterations of genes
leading to a block in plasma cell differentiation might be
redundant in the same neoplasm. The significance of both
these lesions occurring in our case is not known. It is
possible that the deletion of BLIMP1 may represent a
nonspecific or “bystander” deletion due to the large
interstitial deletion of 6q.
Lastly, but importantly, the rarity of TEL rearrangements
in the setting of B-NHL, as described in our case, highlights a
potential diagnostic pitfall if results of cytogenetic analysis
593Diffuse large B-cell lymphomas with TEL/ETV6 translocationare interpreted in the absence of morphologic and phenotypic
data. This is especially pertinent for pediatric hematopoietic
malignancies because rearrangements of TEL are seen in
approximately 25% of cases of B-cell acute lymphoblastic
leukemia [1].References
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